Freeline Therapeutics Holdings plc Quarterly Debt-to-equity in % from Q3 2021 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Freeline Therapeutics Holdings plc quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2023.
  • Freeline Therapeutics Holdings plc Debt-to-equity for the quarter ending September 30, 2023 was 55.1 %, a 8.19% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 55.1 +4.17 +8.19% Sep 30, 2023
Q2 2023 51 +11.8 +30.1% Jun 30, 2023
Q1 2023 61.4 +38.6 +169% Mar 31, 2023
Q4 2022 65.6 +55.3 +536% Dec 31, 2022
Q3 2022 50.9 +42.5 +505% Sep 30, 2022
Q2 2022 39.2 Jun 30, 2022
Q1 2022 22.8 Mar 31, 2022
Q4 2021 10.3 Dec 31, 2021
Q3 2021 8.42 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.